STAT Plus: Pharmalittle: Gilead asks FDA to rescind orphan status for Covid-19 drug; Bristol delays MS drug launch due to coronavirus
Good morning, everyone, and how are you today? We hope you are finding ways to cope during these trying times and are taking the long view. As the sages say: This, too, shall pass. Of course, they never say when, exactly. But this is why the word “optimistic” was invented. On that note, the time has come to fire up the coffee kettle and dig in for another busy day. So here are a few items of interest to help you along. Keep busy. Keep healthy. Keep in touch.
A new multiple sclerosis drug from Bristol Myers Squibb (BMY) was approved by the Food and Drug Administration — a decision that may help Bristol shareholders before patients, STAT explains. The once-daily pill, to be sold under the brand name Zeposia, enters a multiple sclerosis treatment market crowded with entrenched rival medicines. But with people at risk of coronavirus infections and the health care system struggling, Bristol says the “responsible course of action” is to delay a formal commercial launch until the crisis subsides.
Continue to STAT Plus to read the full story…
